Looking for biotech ideas in a specific sweet spot: **market cap over 500M but under 2.5B**.
These are some I have in mind right now:
OCS, RGNX, FDMT, IMRX, PRAX, RARE, SLNO, SLDB
For anyone who follows this space:
* Which of these do you think are the **best setup right now** in terms of risk/reward and upside over the next few years?
* Any you would **avoid completely** and why?
* If you have other biotech names in the 500M–2.5B market-cap range you like more, drop your **top 1–3** and the key catalyst (trial readout, FDA decision, partnership, etc.).